Intravitreal Ranibizumab and Bevacizumab: A Review of Risk
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Ranibizumab (Lucentis), a recombinant monoclonal antibody, blocks all active forms of vascular endothelial growth factor A and was the first treatment for age-related macular degeneration shown to improve visual acuity in a substantial percentage of patients rather than slowing visual loss. Bevacizumab (Avastin) has a similar action, is related to the ranibizumab compound with respect to its structure, but has not been approved by the FDA for intravitreal use and therefore must be utilized only in an off-label setting. While ranibizumab was approved by the FDA at a dose of 0.5 mg per intravitreal injection, the manufacturer recently issued a letter to physicians warning of the increased risk of stroke at the FDA-approved dose as compared to a lower studied dose of 0.3 mg. An interim analysis of the ongoing SAILOR study revealed a 1.2% risk of stroke in the 0.5 mg arm versus 0.3% in the 0.3 mg arm (p = 0.02). It is unclear whether the trend toward a higher risk of stroke in patients receiving 0.5 mg dose of ranibizumab would persist in the final analysis, but details such as causality, topography, and severity of stroke in the SAILOR study should also be delineated. The risks of intraocular use of bevacizumab remain largely unknown at this time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X. O., Logvinova, A., & Greenberg, D. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317977 · Cited by 1,189
Seddon, J. M. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.6.774 · Cited by 354
Despriet, D. D. G., Klaver, C. C. W., Witteman, J. C. M., Bergen, A. A. B., Kardys, I., de Maat, M. P. M., Boekhoorn, S. S., Vingerling, J. R., Hofman, A., Oostra, B. A., et al. (2006) · JAMA · doi:10.1001/jama.296.3.301 · Cited by 348
Cardiovascular Risk Factors and the Long-term Incidence of Age-Related Macular Degeneration
Tan, J. S. L., Mitchell, P., Smith, W., & Wang, J. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.09.033 · Cited by 238
Klein, R., Deng, Y., Klein, B. E. K., Hyman, L., Seddon, J., Frank, R. N., Wallace, R. B., Hendrix, S. L., Kuppermann, B. D., Langer, R. D., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.058 · Cited by 142
Cited by
Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis
Sluimer, J. C., & Daemen, M. J. (2009) · The Journal of Pathology · doi:10.1002/path.2518 · Cited by 367
Biodegradable Implants for Sustained Drug Release in the Eye
Lee, S. S., Hughes, P., Ross, A. D., & Robinson, M. R. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0159-x · Cited by 289
Sedding, D. G., Boyle, E. C., Demandt, J. A. F., Sluimer, J. C., Dutzmann, J., Haverich, A., & Bauersachs, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00706 · Cited by 228
Mitchell, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.585394 · Cited by 102
Guma, M., Rius, J., Duong-Polk, K. X., Haddad, G. G., Lindsey, J. D., & Karin, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902659106 · Cited by 80
Metadata
- Authors
- Dafer, R. M., Schneck, M., Friberg, T. R., & Jay, W. M.
- Venue
- Seminars in Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 22
- Issue
- 3
- Pages
- 201-204
- ISSN
- 0882-0538 (ISSN-L)
- 1744-5205
- OpenAlex
- W2141508695
- Cited by
- 64
- References
- 7
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravitreal Ranibizumab and Bevacizumab: A Review of Risk. https://app.cochat.ai/papers/10.1080/08820530701543024
- The paper
- Dafer, R. M., Schneck, M., Friberg, T. R., & Jay, W. M. (2007). Intravitreal Ranibizumab and Bevacizumab: A Review of Risk. Seminars in Ophthalmology. https://doi.org/10.1080/08820530701543024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.